News & Videos - LILLY AND CO - English - Page 2

Thinking about trading options or stock in TG Therapeutics, Microsoft, Eli Lilly And Co, Chevron, or Alcon? PR Newswire NEW YORK, Jan. 10, 2024 NEW YORK , Jan. 10, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TGTX, MSFT, LLY, CVX, and ALC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of...

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ PR Newswire INDIANAPOLIS, Jan. 4, 2024 INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly...

Lilly to Participate in J.P. Morgan Healthcare Conference PR Newswire INDIANAPOLIS, Jan. 2, 2024 INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11 , 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at...

Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences? PR Newswire NEW YORK, Dec. 27, 2023 NEW YORK , Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CING, GRCL, LLY, EPIX, and CHRS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CING:...

Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS, Dec. 27, 2023 INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 PR Newswire INDIANAPOLIS, Dec. 18, 2023 INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The...

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting PR Newswire INDIANAPOLIS, Dec. 11, 2023 INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell...

Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks PR Newswire INDIANAPOLIS, Dec. 11, 2023 People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American...

Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend PR Newswire INDIANAPOLIS, Dec. 8, 2023 INDIANAPOLIS , Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on March 8, 2024 to shareholders of record at the close of business on Feb. 15, 2024. About Lilly Lilly...

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium PR Newswire INDIANAPOLIS, Dec. 5, 2023 Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women...

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity PR Newswire INDIANAPOLIS, Dec. 5, 2023 Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound ™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m 2 or greater), or those who are overweight (with a BMI of 27 kg/m 2 or greater)...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 PR Newswire INDIANAPOLIS, Dec. 4, 2023 INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender...

Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor PR Newswire INDIANAPOLIS, Dec. 1, 2023 The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two...

Thinking about trading options or stock in Eli Lilly And Co, Apple, Uber Technologies, Pure Storage, or Salesforce? PR Newswire NEW YORK, Nov. 30, 2023 NEW YORK , Nov. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, AAPL, UBER, PSTG, and CRM. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital...

Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego PR Newswire INDIANAPOLIS, Nov. 28, 2023 Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies INDIANAPOLIS , Nov. 28, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly...

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany PR Newswire INDIANAPOLIS, Nov. 17, 2023 Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany . This new facility will further expand the company's global...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 PR Newswire INDIANAPOLIS, Nov. 17, 2023 INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender...

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS, Nov. 14, 2023 INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of...

Lilly to Participate in Evercore ISI HealthCONx Conference PR Newswire INDIANAPOLIS, Nov. 14, 2023 INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28 , 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:50 p.m., Eastern time . A live audio webcast will be...

Thinking about trading options or stock in Salesforce, Applovin, BILL Holdings, Eli Lilly And Co, or Ebix? PR Newswire NEW YORK, Nov. 9, 2023 NEW YORK , Nov. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRM, APP, BILL, LLY, and EBIX. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each...